Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women’s Health Initiative randomized clinical trial.

Authors

null

Rowan T. Chlebowski

Los Angeles BioMedical Research Institute, Torrance, CA

Rowan T. Chlebowski , Aaron K Aragaki , Garnet L Anderson , Kathy Pan , Marian L Neuhouser , JoAnn E Manson , Cynthia A. Thomson , Yasmin Mossavar-Rahmani , Dorothy Lane , Karen Johnson , Jean Wactawski-Wende , Snetselaar Linda , Thomas E Rohan , Juhua Luo , Ana Barac , Ross L Prentice

Organizations

Los Angeles BioMedical Research Institute, Torrance, CA, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, Fred Hutchinson Cancer Research Center, Seattle, WA, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, University of Arizona, Tucson, AZ, Albert Einstein College of Medicine, Bronx, NY, State University of New York at Stony Brook, Stony Brook, NY, University of Tennessee Health Science Center, Memphis, TN, University of Buffalo, Buffalo, NY, University of Iowa, Bloomington, IN, University of Indiana, Bloomington, IN, MedStar Heart and Vascular Institute, Washington, DC

Research Funding

U.S. National Institutes of Health
Other Foundation

Background: Observational studies of dietary fat intake and breast cancer have inconsistent findings. To address this issue, the Women’s Health Initiative (WHI) Dietary Modification (DM) clinical trial assessed a low-fat dietary pattern influence on breast cancer incidence and outcome. Methods: The WHI DM trial is a randomized, controlled clinical trial conducted at 40 US centers, where 48,835 postmenopausal women, aged 50-79 years, with no previous breast cancer and dietary fat intake ≥32% of total energy, were randomly assigned, from 1993-1998, to a usual diet comparison group (60%) or dietary intervention group (40%) with goals to reduce fat intake to 20% of energy and increase vegetables, fruit, and grain intake. This study is registered as: NCT00000611. Results: The dietary intervention significantly reduced fat intake; increased fruit, vegetable and grain intake with modest weight loss (3%) (all P< 0.001). During 8.5 years of dietary intervention, there were 8% fewer breast cancers and deaths from breast cancer were somewhat lower in the intervention group but the rates were not significantly different. However, deaths after breast cancer (breast cancer followed by death from any cause) were significantly reduced in the intervention group, both during intervention (hazard ratio [HR] 0·65 95% confidence interval [CI] 0·45-0·95) and through 16.1 year (median) cumulative follow-up. Now, after long- term, cumulative 19.6 year (median) follow-up, with 3,374 incident breast cancers, the significant reduction in deaths after breast cancer continued (with 1,011 deaths, HR 0·85 95% CI 0·74-0·96) and a significant reduction in deaths from breast cancer (breast cancer followed by death attributed to the breast cancer) emerged (with 383 deaths, HR 0·79 95% CI 0·64-0·97). Conclusions: Adoption of a low-fat dietary pattern associated with increased vegetable, fruit, and grain intake, demonstrably achievable by many, significantly reduced the risk of death from breast cancer in postmenopausal women. To our review, these findings provide the first randomized clinical trial evidence that a dietary change can reduce a postmenopausal woman’s risk of dying from breast cancer. Clinical trial information: NCT00000611

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT00000611

Citation

J Clin Oncol 37, 2019 (suppl; abstr 520)

DOI

10.1200/JCO.2019.37.15_suppl.520

Abstract #

520

Poster Bd #

12

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

Circulating methylated-HOXA9 tumor DNA as a biomarker for mortality in recurrent breast cancer.

First Author: Torben Hansen

Abstract

2023 ASCO Annual Meeting

BMI and mortality in hormone-negative breast cancer: A PLCO trial subgroup analysis.

First Author: Reem Chamseddine

First Author: Emilie Danielle Duchesneau